Arrivent Investigative Site

Lyon 69373

0 studies enrolling now · 2 studies all time

What they study most

Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations, EGFR Uncommon Mutations, Including G719X and S768I, HER2 Exon 20 Mutations, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC)

Studies at this site

• Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations — Running, not enrolling
• Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) — Running, not enrolling